TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs.

Original languageEnglish
Pages (from-to)627-633
Number of pages7
JournalInternational journal of hematology
Volume98
Issue number6
DOIs
Publication statusPublished - Dec 1 2013

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells'. Together they form a unique fingerprint.

  • Cite this